文献速递前列腺增生与排尿功能障碍男科与性医学

iTind治疗良性前列腺增生的性与排尿结局:系统综述与单臂Meta分析

Sexual and Urinary Outcomes After iTind for Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
PubMed 文献 · Urology · 2026-06-13

该系统综述与单臂Meta分析纳入5项前瞻性研究共431例接受iTind治疗的LUTS/BPH男性,12个月时IPSS降低10.44分、Qmax增加5.38 mL/s、PVR减少12.21 mL,性功能无显著变化且射精功能保留。

要点

  • iTind治疗12个月后排尿症状和尿流率显著改善。
  • 勃起功能无统计学显著变化,射精功能保留。
  • 需开展使用验证性性功能量表的对照试验。

核心结论

  • iTind治疗BPH相关LUTS在12个月内产生一致且临床有意义的排尿结局改善。
  • 所有研究中射精功能均保留,勃起功能无显著变化。

研究设计与样本

  • 系统综述与单臂Meta分析,检索PubMed、Embase和Cochrane Central数据库。
  • 纳入5项前瞻性研究,共431例接受iTind治疗的LUTS/BPH男性。
  • 采用随机效应模型进行合并分析。

主要发现

  • 12个月IPSS较基线变化为-10.44分(95%CI -11.79至-9.09;k=4,I2=74%)。
  • 12个月IPSS-QoL变化为-2.08分(95%CI -2.22至-1.93;k=4,I2=0%)。
  • 12个月Qmax增加+5.38 mL/s(95%CI +3.25至+7.51;k=4,I2=93%)。
  • 12个月PVR减少-12.21 mL(95%CI -24.27至-0.16;k=3,I2=77%)。
  • 1个月SHIM/IIEF-5变化+0.68分(95%CI -1.54至+2.90;k=2,I2=75%),3个月变化+1.19分(95%CI -1.42至+3.80;k=2,I2=82%),无统计学显著变化。

关键数值与推荐

  • 12个月外科再干预率范围为0%至4.7%。
  • 射精功能保留,无新发逆行射精。

临床怎么用

  • iTind可作为希望保留射精功能的BPH/LUTS患者的一种治疗选择。
  • 需向患者说明排尿改善的12个月证据及性功能无显著变化的数据。

局限性

  • 仅纳入单臂前瞻性研究,缺乏对照比较。
  • 性功能结局仅2项研究(n=198)报告SHIM/IIEF-5,合并分析异质性高。
  • 部分结局指标研究数量少(k=3或4),异质性中至高。
  • 需开展使用验证性性功能量表的对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To characterize urinary and sexual outcomes following temporary implantable nitinol devices (iTind; Olympus, Japan) therapy for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) through a systematic review and single-arm meta-analysis. MATERIALS AND METHODS: PubMed, Embase, and Cochrane Central databases were queried for prospective studies of men with LUTS/BPH treated with iTind. Primary outcomes were change-from-baseline in the International Prostate Symptom Score (IPSS), IPSS quality-of-life (IPSS-QoL), maximum urinary flow rate (Qmax), post-void residual volume (PVR), and Sexual Health Inventory for Men (SHIM/IIEF-5) score. Ejaculatory function was also assessed. Pooled random-effects meta-analysis was performed. RESULTS: Five prospective studies (431 patients) were included. 12-month pooled change-from-baseline results: IPSS was -10.44 points (95% CI -11.79 to -9.09; k = 4, I2 = 74%). IPSS-QoL was -2.08 points (95% CI -2.22 to -1.93; k = 4, I2 = 0%). Qmax was +5.38 mL/s (95% CI +3.25 to +7.51; k = 4, I2 = 93%). PVR was -12.21 mL (95% CI -24.27 to -0.16; k = 3, I2 = 77%). Two studies (n = 198) reported SHIM/IIEF-5 scores; Pooled analysis at 1 and 3 months was +0.68 points (95% CI -1.54 to +2.90; k = 2, I2 = 75%) and +1.19 points (95% CI -1.42 to +3.80; k = 2, I2 = 82%), respectively, indicating no statistically significant change in erectile function. Ejaculatory function was preserved, with no de novo retrograde ejaculation. 12-month surgical reintervention rates ranged from 0% to 4.7%. CONCLUSION: iTind produces consistent, clinically meaningful improvements in urinary outcomes through 12 months. Ejaculatory function was preserved in all studies, and erectile function showed no significant change. Comparative trials with validated sexual function instruments are warranted.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Loyola-Nieto F, da R Soares GA, Lindenbaum MM, et al. Sexual and Urinary Outcomes After iTind for Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. Urology. 2026. PMID: 42288285. doi:10.1016/j.urology.2026.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。